Media

SynOx Therapeutics Receives Fast Track Designation from U.S. Food and Drug Administration for Emactuzumab for Tenosynovial Giant Cell Tumours (TGCT)

Pretzel Therapeutics Announces Publication in Nature unveiling discovery of novel small molecule activators for the treatment of POLG disorders and other conditions related to mtDNA depletion

BONESUPPORT HOLDING AB (publ) – Information on the impact of tariffs in connection with the company’s import into the United States

Intervacc publishes the 2024 Annual Report

Pretzel Therapeutics Initiates Phase 1 Clinical Study Evaluating PX578, Lead Therapeutic in its Bioenergetics Restoration Franchise

SynOx Therapeutics Announces Board Chair Transition to Align with Advancing Regulatory and Commercialization Strategy

BONESUPPORT™ FILES FDA SUBMISSION FOR CERAMENT® V

U.S. Food and Drug Administration removes clinical hold of Oncopeptides’ pipeline drug OPD5

Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial

Doctrin expands to France as Ramsay Santé chooses platform for outpatient psychiatry digitalization